rhinocort aqueous nasal spray budesonide 64 microgram/actuation spray bottle
johnson & johnson pacific pty ltd - budesonide, quantity: 1.28 mg/ml - spray, suspension - excipient ingredients: glucose; disodium edetate; dispersible cellulose; polysorbate 80; purified water; hydrochloric acid; potassium sorbate - rhinitis: prophylaxis and treatment of seasonal allergic rhinitis. prophylaxis and treatment of perennial allergic rhinitis. nasal polyps: treatment of nasal polyps.
rhinocort aqueous nasal spray budesonide 32 microgram/actuation spray bottle
johnson & johnson pacific pty ltd - budesonide, quantity: 0.64 mg/ml - spray, suspension - excipient ingredients: potassium sorbate; disodium edetate; glucose; purified water; hydrochloric acid; dispersible cellulose; polysorbate 80 - rhinitis: prophylaxis and treatment of seasonal allergic rhinitis. prophylaxis and treatment of perennial allergic rhinitis. nasal polyps: treatment of nasal polyps.
rhinocort aqua 64mcg nasal spray nasal spray, suspension
mcneil sweden ab, sweden - budesonide - nasal spray, suspension - 0.064 mg
rhinocort aqua 64mcg nasal spray
astrazeneca, sweden - budesonide - spray - 0.064 mg
budesonide 64microgramsdose nasal spray
sandoz ltd - budesonide - spray - 64microgram/1dose
rhinocort aqua spray, metered dose
mcneil consumer healthcare division of johnson & johnson inc - budesonide - spray, metered dose - 64mcg - budesonide 64mcg - corticosteroids
rhinocort
astrazeneca pty ltd - budesonide -
rhinocort aqua- budesonide spray, metered
physicians total care, inc. - budesonide (unii: q3oks62q6x) (budesonide - unii:q3oks62q6x) - budesonide 32 ug - rhinocort aqua nasal spray is indicated for the treatment of nasal symptoms of seasonal or perennial allergic rhinitis in adults and children six years of age and older. rhinocort aqua nasal spray is contraindicated in patients with hypersensitivity to any of its ingredients [see warnings and precautions (5.2) ]. teratogenic effects: pregnancy category b. the impact of budesonide on human pregnancy outcomes has been evaluated through assessments of birth registries linked with maternal usage of inhaled budesonide (i.e., pulmicort turbuhaler) and intranasally administered budesonide (i.e., rhinocort aqua nasal spray). the results from population-based prospective cohort epidemiological studies reviewing data from three swedish registries covering approximately 99% of the pregnancies from 1995- 2001 (i.e., swedish medical birth registry; registry of congenital malformations; child cardiology registry) indicate no increased risk for overall congenital malformations from the use of inhaled or intranasal budeso
rhinocort aqua64mcgdose
jntl (malaysia) sdn. bhd. - budesonide -
mylan-budesonide aq spray, metered dose
mylan pharmaceuticals ulc - budesonide - spray, metered dose - 100mcg - budesonide 100mcg - corticosteroids